{"id":"https://openalex.org/W2528577666","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.8572","title":"N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM).","display_name":"N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM).","publication_year":2010,"publication_date":"2010-05-20","ids":{"openalex":"https://openalex.org/W2528577666","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.8572","mag":"2528577666"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2010.28.15_suppl.8572","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.8572","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.8572","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025890579","display_name":"Roxanna Dronca","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. S. Dronca","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045541599","display_name":"Daisy Perez","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. G. Perez","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109347815","display_name":"Jacob B. Allred","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Allred","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016095265","display_name":"William James Maples","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. J. Maples","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032917850","display_name":"Edward T. Creagan","orcid":"https://orcid.org/0000-0002-2976-7075","observed_orcids":["https://orcid.org/0000-0002-2976-7075"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. T. Creagan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039556084","display_name":"BA Pockaj","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. A. Pockaj","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029846347","display_name":"Judith Salmon Kaur","orcid":"https://orcid.org/0000-0002-8889-6870","observed_orcids":["https://orcid.org/0000-0002-8889-6870"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. S. Kaur","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062404970","display_name":"Todd Moore","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. D. Moore","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084942272","display_name":"Benjamin T. Marchello","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. T. Marchello","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5072430869","display_name":"S. N. Markovic","orcid":"https://orcid.org/0009-0001-7914-3869","observed_orcids":["https://orcid.org/0009-0001-7914-3869"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Markovic","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"15_suppl","first_page":"8572","last_page":"8572"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.6288999915122986,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.6288999915122986,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.17000000178813934,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.12240000069141388,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.972000002861023},{"id":"https://openalex.org/keywords/temozolomide","display_name":"temozolomide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/everolimus","display_name":"everolimus","score":0.9940000176429749},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.6700000166893005},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7639999985694885},{"id":"https://openalex.org/keywords/angiogenesis","display_name":"angiogenesis","score":0.48399999737739563},{"id":"https://openalex.org/keywords/vascular-endothelial-growth-factor","display_name":"vascular endothelial growth factor","score":0.7689999938011169},{"id":"https://openalex.org/keywords/immune-response","display_name":"immune response","score":0.5389999747276306},{"id":"https://openalex.org/keywords/mtor-inhibition","display_name":"mTOR inhibition","score":0.6179999709129333},{"id":"https://openalex.org/keywords/alkylating-agents","display_name":"alkylating agents","score":0.6859999895095825},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.6399999856948853},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.597000002861023},{"id":"https://openalex.org/keywords/lung-metastasis","display_name":"lung metastasis","score":0.5640000104904175},{"id":"https://openalex.org/keywords/liver-metastases","display_name":"liver metastasis","score":0.6650000214576721},{"id":"https://openalex.org/keywords/lymph-node-metastasis","display_name":"lymph node metastasis","score":0.9380000233650208},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.4819999933242798}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9241794347763062},{"id":"https://openalex.org/C2779699572","wikidata":"https://www.wikidata.org/wiki/Q421052","display_name":"Everolimus","level":2,"score":0.7053534984588623},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6025232672691345},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5823853015899658},{"id":"https://openalex.org/C2777389519","wikidata":"https://www.wikidata.org/wiki/Q425088","display_name":"Temozolomide","level":3,"score":0.5624023079872131},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.5598219037055969},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5464758276939392},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.4979233741760254},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4644233286380768},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.4135081470012665},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.26578664779663086},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.26115497946739197},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.17987129092216492}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2010.28.15_suppl.8572","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.8572","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.8572","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2005865417","https://openalex.org/W2241618165","https://openalex.org/W2802842062","https://openalex.org/W2240403613","https://openalex.org/W2274963722","https://openalex.org/W2590832032","https://openalex.org/W2891798078","https://openalex.org/W2516000697","https://openalex.org/W2071660661","https://openalex.org/W2007244598"],"abstract_inverted_index":{"8572":[0],"Background:":[1],"A":[2],"recently":[3],"described":[4],"escape":[5],"mechanism":[6],"of":[7,17,31,54,70,73,79,108,164,174,195,217,219,257,278,319,328,353],"melanoma":[8,43],"cells":[9],"exposed":[10],"to":[11,51,179,315,335],"alkylating":[12],"agents":[13,56],"is":[14,188,200],"the":[15,18,29,46,52,71,166,181,184,193,263,286,296,354],"production":[16],"pro-survival":[19],"cytokine":[20],"vascular":[21],"endothelial":[22],"growth":[23],"factor":[24],"(VEGF).":[25],"We":[26,62],"hypothesized":[27],"that":[28,183],"combination":[30,72,327],"TMZ":[32,83,109,329],"and":[33,44,82,141,176,221,252,295,330],"RAD001":[34,74,103,331],"could":[35],"provide":[36],"an":[37],"additive":[38],"therapeutic":[39,338],"benefit":[40],"in":[41,91,360],"metastatic":[42,242],"impact":[45],"antitumor":[47],"immune":[48,58],"response":[49],"due":[50,314],"effect":[53],"both":[55],"on":[57],"cell":[59],"function.":[60],"Methods:":[61],"conducted":[63],"a":[64,161,171,283,337],"single":[65],"arm":[66],"phase":[67],"II":[68],"trial":[69],"(10":[75],"mg/day":[76],"for":[77],"5":[78,113],"7":[80],"days)":[81,90],"(200":[84],"mg/m2":[85],"days":[86],"1-5":[87],"every":[88],"28":[89],"patients":[92,206,258],"with":[93,102,123,255,357],"stage":[94],"IV":[95],"unresectable":[96],"MM.":[97],"Patients":[98],"(pts)":[99],"began":[100],"therapy":[101,125,214,313],"1":[104,111,310],"week":[105,154],"before":[106],"initiation":[107],"(cycle":[110],"=":[112,117],"weeks,":[114],"other":[115,358],"cycles":[116],"4":[118,277],"weeks).":[119],"Pts":[120],"previously":[121],"treated":[122],"systemic":[124],"(excluding":[126],"study":[127,168,225],"agents)":[128],"were":[129,134,207,244,273],"eligible.":[130],"Major":[131],"exclusion":[132],"criteria":[133],"active":[135],"brain":[136],"metastases,":[137],"abnormal":[138],"liver/renal":[139],"function,":[140],"poor":[142],"performance":[143],"status":[144],"(PS":[145],">":[146,204],"2).":[147],"The":[148,224,239,326],"primary":[149],"end":[150,211],"point":[151],"was":[152,289,299,306],"9":[153],"progression":[155],"free":[156],"survival":[157],"(PFS9)":[158],"rate.":[159],"With":[160],"sample":[162],"size":[163],"39,":[165],"one-stage":[167],"design":[169],"had":[170],"significance":[172],"level":[173],"0.10":[175],"90%":[177],"power":[178],"test":[180],"hypothesis":[182],"true":[185],"PFS9":[186,208,274],"rate":[187],"at":[189,196],"most":[190,240],"35%":[191],"vs":[192],"alternative":[194],"least":[197],"55%.":[198],"Regimen":[199],"considered":[201],"promising":[202],"if":[203],"17":[205,268],"successes.":[209,275],"Secondary":[210],"points":[212],"included":[213],"associated":[215],"changes":[216],"biomarkers":[218],"angiogenesis":[220],"immunity.":[222],"Results:":[223],"accrued":[226],"49":[227],"pts":[228,281],"(1":[229],"ineligible)":[230],"from":[231],"01/08-10/08":[232],"(median":[233],"age:":[234],"60":[235],"years":[236],"[range":[237],"28-84]).":[238],"common":[241],"sites":[243],"lungs":[245],"(43%)":[246],"followed":[247],"by":[248],"lymph":[249],"nodes":[250],"(28%)":[251],"liver":[253],"(20%),":[254],"27%":[256],"having":[259],"prior":[260],"chemotherapy.":[261],"Of":[262],"first":[264],"39":[265],"evaluable":[266],"pts,":[267],"(44%,":[269],"95%":[270],"CI:":[271,293,303],"28-60%)":[272],"Overall":[276],"48":[279],"(8%)":[280],"achieved":[282],"partial":[284],"response,":[285],"median":[287,297],"PFS":[288],"2.4":[290],"months":[291],"(95%":[292,302],"2.1\u20134.0),":[294],"OS":[298],"8.6":[300],"mos":[301],"7.1-12.2).":[304],"Treatment":[305],"well":[307],"tolerated,":[308],"only":[309],"pt":[311],"discontinued":[312],"toxicity":[316],"(hyperlipidemia).":[317],"Results":[318],"correlative":[320],"laboratory":[321],"studies":[322],"are":[323],"forthcoming.":[324],"Conclusions:":[325],"did":[332],"not":[333],"appear":[334],"offer":[336,348],"advantage":[339],"over":[340],"TMZ-alone":[341],"historic":[342],"controls.":[343],"Pending":[344],"biomarker":[345],"analysis":[346],"may":[347],"insights":[349],"into":[350],"potential":[351],"combinations":[352],"current":[355],"regimen":[356],"treatments":[359],"advanced":[361],"melanoma.":[362],"Author":[363],"Disclosure":[364],"Employment":[365],"or":[366,370],"Leadership":[367],"Position":[368],"Consultant":[369],"Advisory":[371],"Role":[372],"Stock":[373],"Ownership":[374],"Honoraria":[375],"Research":[376],"Funding":[377],"Expert":[378],"Testimony":[379],"Other":[380],"Remuneration":[381],"Novartis":[382]},"counts_by_year":[{"year":2015,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-10-14T00:00:00"}